Apolipoprotein B versus non-high-density lipoprotein cholesterol: And the winner is...

Circulation

Volumn 112, Issue 22, 2005, Pages 3366-3367

  Sniderman, Allan D ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Apolipoproteins; Cholesterol; Editorials; Risk factors

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN CHOLESTEROL;

ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHOLESTEROL METABOLISM; EDITORIAL; ENDOTHELIUM INJURY; HIGH RISK POPULATION; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; LIPID OXIDATION; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK FACTOR; BLOOD; METABOLISM; NOTE; PRACTICE GUIDELINE; PREDICTION AND FORECASTING; RISK;

APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; HUMANS; LIPOPROTEINS; PRACTICE GUIDELINES; PREDICTIVE VALUE OF TESTS; RISK;

EID: 33644876621     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.583336     Document Type: Editorial

References (20)

1. Levenson JW, Skerrett PJ, Gaziano JM. Reducing the global burden of cardiovascular disease: the role of risk factors. Prev Cardiol. 2002;5:188-199.
2. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375-3383.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
4. Blue Cross Blue Shield. Apolipoprotein B Testing for the Diagnosis and Management of Cardiovascular Disease. Medical Policy Reference Manual. Chicago, Ill: Blue Cross Blue Shield; 2003.
5. 100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326-333.
6. Lui J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diab Care. 2005;28:1916-1921.
7. Schulze MB, Shai I, Manson JE, Li T, Rifai N, Jiang R, Hu FB. Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes. Diabetologia. 2005;47:2129-2136.
8. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413-1419.
9. Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, Hu FB. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care. 2004;27:1991-1997.
10. Keulen EP, Kruijshoop M, Schaper NC, Hoeks AG, de Bruin TA. Increased intimamedia thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arterioscler Thromb Vasc Biol. 2002;22:283-288.
11. Simon A, Chironi G, Gariepy J, Del Pino M, Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis. 2005;179:339-344.
12. Wagner AM, Perez A, Zapico E, Ordonez-Llanos J. Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care. 2003;26:2048-2051.
13. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med. 2004;42:1355-1363.
14. -/- mice. Arterioscler Thromb Vasc Biol. 2001;21:1567-1570.
15. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipoprotein versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet. 2003;361:777-780.
16. Sniderman AD, StPierre A, Cantin B, Dagenais GR, Despres JP, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol. 2003;91:1173-1177.
17. Sattar N, Williams K, Sniderman AD, D'Agostino R Jr, Haffner SM. Comparison of the associations of apoB and non-HDL cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Study (IRAS). Circulation. 2004;110:2687-2693.
18. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B: IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem. 1994;40:586-592.
19. Avagaro P, Bittolo Bon G, Cazzolato G, Quinci GB. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet. 1979;313:901-903.
20. Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO Jr. Association of coronary atherosclerosis with hyperapobetalipoproteinemia. Proc Natl Acad Sci U S A. 1980;77:604-608.